Ionis Pharmaceuticals Inc



-52.0% last 12 months

Market Cap

$4.24 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$25.04 - $64.37

The lowest and highst price in the last 52 weeks.

Price-Earnings Ratio


The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Market Cap $4.24 Billion
Enterprise Value $3.56 Billion
Dividend Yield $0.00 (0.0%)
1 Year Return -52.0%
52-Week High $64.37
52-Week Low $25.04
Beta 1.18
Outstanding Shares 141 Million
Avg 30 Day Volume 1.07 Million


P/E Ratio -7.14
PEG -4.29
Earnings per Share -$4.22
Price to Sales Ratio 7.47
Price to Book Ratio 9.96
Revenue to Enterprise Value 5.38
EBIT to Enterprise Value -13.01
Total Debt to Enterprise Value 0.37
Debt to Equity 2.46


Revenue $661 Million
Gross Profit $649 Million
EBIT -$273 Million
Net Income -$593 Million
Profit Margin -89.82%
Quarterly Earnings Growth (YoY) +166.5%
Return on Equity -111.86%
Return on Assets -24.58%
Return on Invested Capital -12.81%

Insider trades

No purchases

No sells

No purchases

4,334 shares sold (1 transactions)

No purchases

No sells

No purchases

No sells

Q2 2021 Q3 2021 Q4 2021 Q1 2022

About Ionis Pharmaceuticals Inc

CEO: Brett Monia

Employees: 817

Industry: Pharmaceutical Preparation Manufacturing

Ionis Pharmaceuticals is a biotechnology company based in Carlsbad, California that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza , Tegsedi , and WAYLIVRA and has 4 drugs in pivotal studies: tominersen for Huntington’s disease, tofersen for SOD1-ALS, AKCEA-APO-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis. The company was named Isis Pharmaceuticals until December 2015.

Similar stocks

Northwest Biotherapeutics Inc
Northwest Biotherapeutics Inc
National Research Corp
National Research Corp
Nymox Pharmaceutical Corp
Nymox Pharmaceutical Corp